Leading international VC providing capital and expertise to support breakthrough therapies and medical products
TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.
TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.
The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.
Venture Capital, Growth Capital, International, Life Science, Innovation, Drug Development, Biotech, Medtech, HealthTech, Diagnostics, Drug Development, and Medical Technologies
TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
HTGF | High-Tech Gründerfonds Venture Capital and Private Equity Principals | HTGF | High-Tech Gründerfonds Venture Capital and Private Equity Principals | Other 26 Oct 2023 | |